The Quantellect read.As of Nov 19, 2026, 11 active firms cover PTC Therapeutics Inc: 10 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $75.00 to $137.00, a moderate spread. The average target of $101.00 sits 68% above the current $60.23. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.52 next quarter toward $3.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy1091%
Neutral19%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$101.00
+67.7% upside
Average target across 11 active firms as of Nov 19, 2026 vs $60.23 current
Highest Target$137.00
Average Target$101.00
Lowest Target$75.00
Detailed analyst forecasts for PTCT
Showing 1–10 of 10 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 10 of 11 active firms rate PTCT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PTCT EPS & revenue forecast
EPS · NEXT QUARTER
$0.52
Range $-0.01 – $1.38 · 7 analysts · -1830% YoY
Next period, 7 analysts expect PTC Therapeutics Inc to earn $0.52 a share (range $-0.01 – $1.38), versus $-0.03 a year earlier. Full-year consensus is $0.94, growing to $3.19 the year after.
REVENUE · NEXT QUARTER
$313.4M
Range $291.6M – $341.4M · 7 analysts · +15% YoY
Revenue is expected to reach $313.4M (range $291.6M – $341.4M), +15.0% year-over-year. Full-year consensus is $1.3B, rising to $1.4B next year.
Top analysts covering PTC Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PTCT.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Buy
$104.00+72.7% to target
Overall win rate
64%
+ Follow
#2
Joel Beatty
Baird · Rank #71
Buy
$70.00+16.2% to target
Overall win rate
50%
+ Follow
#3
Brian Cheng
JP Morgan · Rank #87
Buy
No targeton PTCT
Overall win rate
51%
+ Follow
#4
Paul Choi
Goldman Sachs · Rank #110
Sell
$70.00+16.2% to target
Overall win rate
52%
+ Follow
#5
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$137.00+127.5% to target
Overall win rate
38%
+ Follow
PTCT stock forecast FAQ
What is PTCT's average 12-month price target?+
The 11 active firms with a live target average $101.00 for PTC Therapeutics Inc over the next 12 months, ranging from a $137.00 high to a $75.00 low, as of Nov 19, 2026.
Is PTCT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PTCT?+
The Street-high target is $137.00 (Cantor Fitzgerald), and the Street-low is $75.00 (RBC Capital). The average of all 11 active-firm targets is $101.00.
How many active Wall Street firms cover PTCT?+
11 active firms have a recognized rating on PTC Therapeutics Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PTCT?+
Among analysts who currently cover PTCT, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Buy with a $104.00 target.
What is PTC Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.52 per share (range $-0.01 – $1.38) across 7 analysts. Full-year EPS is projected at $0.94, rising to $3.19 the following year.
How much revenue is PTC Therapeutics Inc expected to report next quarter?+
Consensus revenue is $313.4M (range $291.6M – $341.4M). Full-year revenue is projected at $1.3B, growing to $1.4B next year.
Have analysts been upgrading or downgrading PTCT lately?+
As of Nov 19, 2026, 10 of 11 active firms rate PTCT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PTCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.